Form 13-F position report

ENANTA PHARMACEUTICALS INC

Reported by JACOBS LEVY EQUITY MANAGEMENT INC

Company profile Manager portfolio Source filing
ENTA CUSIP 29251M106 Manager CIK 0000884414
Latest reported change

Reported 253,814 shares, down 5,739 (2.2%) from the prior quarter.

Reported value 26.2%; share count -2.2% vs. the prior quarter.

Reduced
% of reported 13F value 0.1% This manager · Q3 2021
Shares 253,814 Quarter-end amount reported
Reported value $14,419,000 Fair value at quarter end
Consecutive quarters held 10 Through Q3 2021

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q4 2025 Reduced 0 -169,048 (-100.0%) 0 $0 2026-02-13
Q3 2025 Reduced 169,048 -23,022 (-12.0%) < 0.01% $2,023,505 2025-11-17
Q2 2025 Reduced 192,070 -74,698 (-28.0%) < 0.01% $1,452,049 2025-08-14
Q1 2025 Reduced 266,768 -23,243 (-8.0%) < 0.01% $1,472,559 2025-05-15
Q4 2024 Added 290,011 +98,285 (51.3%) < 0.01% $1,667,563 2025-02-14
Q3 2024 Reduced 191,726 -2,841 (-1.5%) < 0.01% $1,986,281 2024-11-14
Q2 2024 Reduced 194,567 -163 (-0.1%) 0.01% $2,523,534 2024-08-14
Q1 2024 Reduced 194,730 -366,291 (-65.3%) 0.02% $3,399,986 2024-05-15
Q4 2023 Added 561,021 +215,370 (62.3%) 0.03% $5,279,208 2024-02-14
Q3 2023 Reduced 345,651 -1,697 (-0.5%) 0.02% $3,860,922 2023-11-17
Q2 2023 Added 347,348 +893 (0.3%) 0.04% $7,433,247 2023-08-14
Q1 2023 Reduced 346,455 -2,603 (-0.7%) 0.09% $14,010,640 2023-05-15
Q4 2022 Reduced 349,058 -3,245 (-0.9%) 0.11% $16,238,179 2023-02-14
Q3 2022 Added 352,303 +54,771 (18.4%) 0.14% $18,274,000 2022-11-15
Q2 2022 Added 297,532 +19,109 (6.9%) 0.11% $14,064,000 2022-08-15
Q1 2022 Added 278,423 +8,293 (3.1%) 0.13% $19,818,000 2022-05-16
Q4 2021 Added 270,130 +16,316 (6.4%) 0.14% $20,200,000 2022-02-14
Q3 2021 Reduced 253,814 -5,739 (-2.2%) 0.1% $14,419,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

159 managers reported ENANTA PHARMACEUTICALS INC for Q3 2021.

Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 3,595,053 -76,953 < 0.01% $204,237,000 30 qtrs
FARALLON CAPITAL MANAGEMENT LLC Unchanged 1,995,000 0 0.53% $113,336,000 17 qtrs
ARMISTICE CAPITAL LLC Reduced 1,836,000 -164,000 1.77% $104,303,000 22 qtrs
VANGUARD GROUP INC Reduced 1,800,363 -56,656 < 0.01% $102,278,000 34 qtrs
STATE STREET CORPORATION Added 1,072,182 +18,107 < 0.01% $60,911,000 33 qtrs
FIRST MANHATTAN CO Added 969,736 +936,536 0.2% $55,090,000 21 qtrs
NORTHERN TRUST CORPORATION Added 959,048 +310,246 < 0.01% $54,483,000 34 qtrs
Krensavage Asset Management LLC Reduced 936,777 -2,873 16.69% $53,218,000 27 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 756,585 -41,143 0.06% $42,982,000 23 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 610,866 -33,922 0.01% $34,703,000 27 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2021
Filed
November 15, 2021
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
222,935
Shared
0
None
30,879

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.